vTv Therapeutics Inc (OQ:VTVT)

Mar 13, 2024 08:00 am ET
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter...
Mar 04, 2024 08:00 am ET
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the submission...
Mar 01, 2024 08:00 am ET
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company...
Feb 28, 2024 08:00 am ET
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has...
Feb 22, 2024 03:00 pm ET
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
Nov 09, 2023 04:30 pm ET
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results...
Nov 08, 2023 08:00 am ET
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that its Chief...
Nov 02, 2023 08:00 am ET
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment...
Nov 01, 2023 08:00 am ET
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that it has...
Sep 27, 2023 08:30 am ET
CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE
WESTON, Fla. and ANN ARBOR, Mich., Sept. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, and Michigan Medicine, a part of the University of Michigan and one of the nation's leading academic medical centers, announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex's azeliragon in decrea
Sep 26, 2023 08:30 am ET
Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer
Initiation of Clinical Study at Allegheny Health Network Seeks to Provide Treatment Options to Pancreatic Cancer Patients
Sep 18, 2023 08:30 am ET
CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA
Initiation of Clinical Study at Lenox Hill Hospital Seeks to Provide New Option for Treatment of Newly Diagnosed Unmethylated Glioblastoma
Aug 11, 2023 04:30 pm ET
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results...
Jun 16, 2023 08:00 am ET
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decli
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that Cantex...
Jun 15, 2023 07:33 am ET
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
WESTON, Fla., June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.
May 24, 2023 09:00 am ET
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that the United States Patent and...
May 11, 2023 04:15 pm ET
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter...
Apr 20, 2023 08:00 am ET
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patie
WESTON, Fla. and ANN ARBOR, Mich., April 20, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Michigan Medicine, a part of the University of Michigan and one of the nation's leading academic medical centers, announced today the initiation of a randomized double-blind, placebo-controlled, multicenter, phase 2/3 clinical study to evaluate the safety and efficacy of azeliragon in decreasing the incidence of acute kidney injury and other life-thre
Mar 06, 2023 05:56 pm ET
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of Type 1 diabetes, today reported financial results for the fourth quarter and year...
Feb 27, 2023 07:02 am ET
Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma
Cantex is developing azeliragon as a once-a-day pill for the treatment of glioblastoma and other cancers
Feb 01, 2023 05:00 pm ET
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice...
Jan 09, 2023 07:00 am ET
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA
WESTON, Fla., Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.
Dec 13, 2022 08:15 am ET
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Chief Financial Officer,...
Nov 10, 2022 05:25 pm ET
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the third quarter ended September 30, 2022,...
Aug 15, 2022 06:43 pm ET
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June 30, 2022, and...
Jul 27, 2022 07:00 am ET
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that Paul Sekhri will lead the company as President and Chief...
Jul 25, 2022 09:31 am ET
Thinking about buying stock in Aethlon Medical, Tonix Pharmaceuticals, REE Automotive, Kaival Brands, or vTv Therapeutics?
NEW YORK, July 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AEMD, TNXP, REE, KAVL, and VTVT.
Jul 25, 2022 07:00 am ET
vTv Therapeutics Announces Investment by CinRx Pharma
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”). Under the terms of the agreements, CinPax acquired 4,154,549...
Jun 04, 2022 11:00 am ET
vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patien
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that the results from the JDRF-supported mechanistic study...
Jun 01, 2022 08:30 am ET
Thinking about buying stock in Tonix Pharmaceuticals, View, vTv Therapeutics, TherapeuticsMD, or Cassava Sciences?
NEW YORK, June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, VIEW, VTVT, TXMD, and SAVA.
Jun 01, 2022 06:54 am ET
vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $25 million investment by G42 Investments AI Holding RSC Ltd (“G42 Investments”). Under the terms of the agreements, G42 Investments acquired 10,386,274...
May 12, 2022 07:45 am ET
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022, and provided an update on the progress of its clinical programs. Recent Achievements and Outlook Corporate Strategic Focus. We are...
Mar 29, 2022 09:47 pm ET
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C., March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on the progress of its clinical programs.
Mar 03, 2022 07:48 pm ET
vTv Therapeutics Announces CEO Transition
HIGH POINT, N.C., March 3, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive Officer. Mr. Nelson joined the vTv Board of Directors in 2020, and currently serves as Executive Vice President Corporate & Business Development of Vericast, and Executive Vice President Corporate Development for MacAndrews & Forbes. He brings more than 25 years of business and legal experience
Jan 13, 2022 08:30 am ET
vTv Therapeutics Shares Updated Corporate Presentation
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral...
Dec 06, 2021 05:19 pm ET
vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes, today announced the prioritization of its lead program TTP399 as it gears up for Phase 3...
Nov 09, 2021 08:30 am ET
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs. “We plan to refocus vTv’s strategy on TTP399.  TTP399 is...
Oct 20, 2021 09:00 am ET
vTv Therapeutics Announces Deepa Prasad as New President and CEO
HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as President and Chief Executive Officer, effective immediately. Stephen L. Holcombe who previously served as vTv's President and Chief Executive Officer will be retiring.
Oct 12, 2021 07:30 am ET
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced positive results of a mechanistic study of TTP399 in...
Sep 27, 2021 10:55 am ET
Thinking about buying stock in Camber Energy, Rewalk Robotics, vTv Therapeutics, Quantumscape, or Northern Dynasty Minerals?
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, RWLK, VTVT, QS, and NAK.
Sep 24, 2021 08:31 am ET
Thinking about buying stock in Capricor Therapeutics, vTv Therapeutics, Li-Cycle Holdings, Predictive Oncology, or Rewalk Robotics?
NEW YORK, Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, VTVT, LICY, POAI, and RWLK.
Sep 23, 2021 04:30 pm ET
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced results of a multiple ascending dose study evaluating...
Aug 04, 2021 04:30 pm ET
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs. “We held our first, highly-productive meeting with the FDA following...
Jun 29, 2021 07:30 am ET
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that it will be presenting data from the clinical...
Jun 22, 2021 08:30 am ET
Thinking about buying stock in vTv Therapeutics, Score Media and Gaming, Bio-Path Holdings, Anavex Life Sciences, or Atossa Therapeutics?
NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTVT, SCR, BPTH, AVXL, and ATOS.
Jun 22, 2021 07:30 am ET
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize...
May 05, 2021 04:10 pm ET
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2021, and provided an update on the progress of its clinical programs. “The vTv team continued to build on the clinical success of our type...
Apr 13, 2021 07:30 am ET
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that the U.S. Food and Drug Administration (FDA) has...
Apr 12, 2021 04:30 pm ET
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported...
Mar 23, 2021 07:30 am ET
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using TTP399, the company’s oral glucokinase activator. The patent number is 10,952,993...
Mar 18, 2021 04:05 pm ET
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study...
Mar 08, 2021 04:05 pm ET
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C. Wainwright...
Feb 25, 2021 07:30 am ET
Thinking about buying stock in GameStop, AMC Entertainment, Dynatronics Corp, Selecta Biosciences, or vTv Therapeutics?
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, DYNT, SELB, and VTVT.
Feb 24, 2021 04:30 pm ET
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2020, and provided an update on the progress of its clinical programs. “Despite the challenges of operating through a global...
Feb 23, 2021 10:30 am ET
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) and inflammatory diseases, today announced that the results from the...
Feb 17, 2021 04:05 pm ET
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a phase 1 multiple...
Feb 04, 2021 07:30 am ET
Thinking about buying stock in Anavex Life Sciences, Lizhi, vTv Therapeutics, Atossa Therapeutics, or Cyclo Therapeutics?
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, LIZI, VTVT, ATOS, and CYTH.
Jan 06, 2021 04:30 pm ET
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci...
Dec 15, 2020 06:15 pm ET
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as...
Dec 15, 2020 08:05 am ET
Aditum Bio Announces Formation of Third Company, Anteris Bio
OAKLAND, Calif., Dec. 15, 2020 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Anteris Bio, a portfolio company developing a new therapy for the treatment of renal disease. Anteris Bio is being formed following the successful in-licensing of ANT-401 from vTv Therapeutics (NASDAQ:VTVT).   
Dec 15, 2020 07:41 am ET
Thinking about buying stock in Anavex Life Sciences, Veru Inc, vTv Therapeutics, BioCardia, or 22nd Century Group?
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, VERU, VTVT, BCDA, and XXII.
Dec 15, 2020 07:30 am ET
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a...
Dec 11, 2020 07:30 am ET
Thinking about buying stock in Walt Disney, vTv Therapeutics, 22nd Century Group, Lexicon Pharmaceuticals, or Ardelyx?
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, VTVT, XXII, LXRX, and ARDX.
Nov 24, 2020 04:30 pm ET
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. “The LPC...
Nov 05, 2020 04:30 pm ET
vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the progress of its clinical programs. “Following our decision to conclude enrollment in the Elevage...
Nov 04, 2020 07:30 am ET
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease (AD) in people with type 2 diabetes...
Oct 29, 2020 07:30 am ET
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Di
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event on November 4, 2020. The presentation will provide a general study update and data...
Sep 23, 2020 07:30 am ET
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study (NCT03335371) that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D). Newly reported data...
Sep 16, 2020 07:30 am ET
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at the 56th Annual Meeting of the European Association for the Study of...
Sep 15, 2020 07:30 am ET
vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Edward P. Taibi, Executive Vice President of MacAndrews & Forbes Incorporated (“MacAndrews”), to the vTv Board of Directors. Effective August 31, 2020, Mr. Taibi will serve a term...
Aug 03, 2020 04:30 pm ET
vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020, and provided an update on the progress of its clinical programs. “Building on the successful phase 2 study completed earlier this year...
Jul 27, 2020 07:30 am ET
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional...
Jun 15, 2020 09:31 am ET
Thinking about buying stock in vTv Therapeutics, Norwegian Cruise Line, IZEA Worldwide, Spirit Airlines, or Nokia?
NEW YORK, June 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTVT, NCLH, IZEA, SAVE, and NOK.
Jun 13, 2020 11:00 am ET
vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjun
HIGH POINT, N.C., June 13, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today made two presentations at the American Diabetes Association’s 80th Scientific Sessions. The clinical data presented from the positive Phase 2...
May 27, 2020 07:30 am ET
vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th...
May 22, 2020 04:30 pm ET
vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns...
May 07, 2020 04:30 pm ET
vTv Therapeutics Announces 2020 First Quarter Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020, and provided an update on recent clinical achievements. “In spite of the challenges presented by the COVID-19 pandemic, we are...
Feb 20, 2020 06:58 pm ET
vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent clinical achievements. “Our success in enrolling and executing clinical trials for our...
Feb 10, 2020 07:00 am ET
vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D). TTP399 is a novel, liver-selective...
Feb 07, 2020 04:05 pm ET
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D) on Monday,...
Dec 02, 2019 07:30 am ET
vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general...
Oct 30, 2019 05:30 pm ET
vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter that ended September 30, 2019, and provided an update on recent achievements, events, and its ongoing clinical trials in type 1 diabetes and Alzheimer’s...
Oct 03, 2019 07:30 am ET
vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City on Tuesday,...
Sep 18, 2019 07:30 am ET
vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th Annual Meeting of the European Association for the Study of Diabetes. In a poster...
Sep 11, 2019 07:30 am ET
vTv Therapeutics to Present Posters at Two Scientific Conferences in September
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company with leading programs focused on the development of orally administered treatments for diabetes, Alzheimer’s disease and inflammatory disorders, today announced it...
Sep 04, 2019 07:30 am ET
vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company...
Aug 06, 2019 04:05 pm ET
vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences 
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it will be participating in the...
Jul 31, 2019 04:30 pm ET
vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update on recent achievements and upcoming events. “We made significant progress during the second quarter,” said...
Jul 15, 2019 04:59 pm ET
vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral presentation at the 2019 Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, July
Jun 27, 2019 04:30 pm ET
vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes.
Jun 06, 2019 08:00 am ET
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with type 1 diabetes (T1D).
May 01, 2019 04:30 pm ET
vTv Therapeutics Announces 2019 First Quarter Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent achievements and upcoming events.
Apr 18, 2019 08:40 am ET
Report: Developing Opportunities within Apergy, vTv Therapeutics, Arcimoto, Lipocine, Zealand Pharma A/S, and AquaBounty Technologies — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Apergy Corporation (NYSE:APY), vTv Therapeutics Inc. (NASDAQ:VTVT), Arcimoto,...
Mar 28, 2019 04:30 pm ET
vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that its Chief Scientific Officer, Carmen Valcarce, will be presenting at the 14th International Con
Mar 18, 2019 09:00 am ET
vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of the Company’s Class A common stock (the “Common Stock”) at a price of $1.65 per share for aggregate gross proceeds of approximately $6.0 million. The offering is expected to close on or about March 20, 2019, subject to the satisfaction of customary closing conditions.
Feb 27, 2019 08:30 am ET
vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year that ended December 31, 2018, and provided an update on recent achievements and upcoming events.
Jan 16, 2019 02:00 pm ET
vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase (GK) activator, as a potential treatment for diabetes. The paper reviews the s
Dec 31, 2018 08:31 am ET
Thinking about buying stock in Aurinia Pharmaceuticals Inc, Eagle Bancorp, Canada Goose Holdings Inc., New Age Beverages Corp, or vTv Therapeutics Inc.?
NEW YORK, Dec. 31, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUPH, EBMT, GOOS, NBEV, and VTVT.
Dec 03, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's C
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Honeywell International Inc. (NYSE:HON), Tabula Rasa Healthcare Inc....
Nov 19, 2018 04:00 pm ET
vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City.
Nov 08, 2018 05:21 pm ET
vTv Therapeutics Announces Third Quarter 2018 Results and Update
vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achievements and upcoming events.
Oct 29, 2018 06:30 pm ET
vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class A Comm
Oct 24, 2018 09:00 am ET
vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that a subgroup analysis from the azeliragon Phase 3 STEADFAST trial was presented at the 11th C
Oct 24, 2018 07:40 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Tabula Rasa Healthcare, Interpublic Group of Companies, Travelport Worldwide, Weight Watchers International, vTv Therapeutics, and U
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tabula Rasa Healthcare Inc. (NASDAQ:TRHC), Interpublic Group of Companies,...
Oct 16, 2018 04:30 pm ET
vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheim
Oct 03, 2018 09:31 am ET
Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?
NEW YORK, Oct. 3, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTEA, IGC, OGEN, SFIX, and VTVT.
Aug 30, 2018 04:30 pm ET
vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Con
Aug 03, 2018 07:30 am ET
vTv Therapeutics Announces Second Quarter 2018 Results and Update
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.
Jun 22, 2018 09:00 am ET
vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Fla., June 22–26, 2018.
Jun 12, 2018 04:30 pm ET
vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal
Jun 12, 2018 08:25 am ET
Research Report Identifies Avangrid, Entercom Communications, Kennedy-Wilson, Emerson Electric, Amgen, and vTv Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avangrid, Inc. (NYSE:AGR), Entercom Communications Corporation (NYSE:ETM),...
May 31, 2018 07:33 am ET
vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thaila
May 15, 2018 04:30 pm ET
vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial and operational results for the first quarter that ended March 31, 2018.
May 09, 2018 04:30 pm ET
vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease, despite not meeting co-primary endpoints, identified a subpopulation that showed
Apr 09, 2018 04:46 pm ET
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint. Patients taking azeliragon compared with placebo did not
Mar 22, 2018 05:00 pm ET
vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study, being conducted with support from JDRF, the leading g
Feb 27, 2018 05:15 pm ET
vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
vTv Therapeutics Inc. (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the fourth quarter and full year that ended December 31, 2017.
Feb 16, 2018 08:25 am ET
Detailed Research: Economic Perspectives on OUTFRONT Media, Mylan N.V, Axcelis Technologies, Patterson-UTI Energy, SAExploration, and vTv Therapeutics — What Drives Growth in Today's Competitive Lands
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OUTFRONT Media Inc. (NYSE:OUT), Mylan N.V....
Dec 21, 2017 04:30 pm ET
vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a global licensing agreement with Reneo Pharmaceuticals, a privately-held biotechnology company focused on developing treatments for orphan diseases. The agreement grants Reneo Pharmaceuticals exclusive worldwide rights to r
Dec 21, 2017 03:00 am ET
Dec 04, 2017 07:55 am ET
Market Trends Toward New Normal in Patterson-UTI Energy, SAExploration, vTv Therapeutics, Outfront Media, Mylan N.V, and Axcelis Technologies — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Patterson-UTI Energy, Inc. (NASDAQ:PTEN), SAExploration Holdings,...
Nov 13, 2017 07:30 am ET
vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimer’s Disease
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that the Company will host a key opinion leader (KOL) presentation and webcast focused on the current state of clinical development in Alzheimer’s disease in New York City on Thursday, November 16, 2017 from 8:00 am to 10:00 am ET.
Nov 08, 2017 04:35 pm ET
vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today the initiation of simplici-T1, an adaptive Phase1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of TTP399 in adult patients with type 1 diabetes (T1D). The study is designed to evaluate whether TTP399 is well tolerated when administered as an add-on to insulin therapy and can improve daily glucose profiles and HbA1c in people living with T1D. Results from the Phase1b part of the study are expected in early 2018. The study is being conducted with support fr
Nov 02, 2017 08:30 am ET
Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings – Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Echelon Corporation (NASDAQ:ELON), NII Holdings, Inc....
Nov 01, 2017 04:30 pm ET
vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results
vTv Therapeutics Inc. (vTv Therapeutics) (Nasdaq:VTVT) today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2017.
Oct 30, 2017 07:00 am ET
vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
vTv Therapeutics Inc. (Nasdaq:VTVT), today announced that the Company will present three posters on clinical trials related to its lead investigational Alzheimer’s program candidate, azeliragon, at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference on November 1 - 4, 2017 in Boston. vTv is currently studying azeliragon in two identical, randomized, double-blind, placebo-controlled Phase 3 trials investigating its efficacy as a potential treatment of mild Alzheimer’s disease.
Nov 15, 2016 04:23 pm ET
Horizon Technology Finance Leads $25 Million Venture Loan Facility for vTv Therapeutics
FARMINGTON, Conn. and HIGH POINT, N.C., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (NASDAQ:HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, announced today that Horizon and Silicon Valley Bank (“SVB”), the bank of the world’s most innovative companies and their investors, have provided a $25 million venture loan facility for vTv Therapeutics Inc. (NASDAQ:VTVT) (“vTv”), a cli...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.